The role of miR-6884-5p in epithelial-mesenchymal transition in non-small cell lung cancer
Aging · 2024
DOI: 10.18632/aging.205474 ↗At a glance
Journal article in Aging, 2024. Written by Lianyong Zhang and 6 co-authors. Institution: Department of Pulmonary and Critical Care Medicine (PCCM) Ward II, Cangzhou Central Hospital, Cangzhou 061000, Hebei, China. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, MicroRNAs. Cited 2 times so far (Crossref); 46 references. The full text is freely available in PubMed Central.
Abstract (original language)
Significant progress has been made in the management of non-small cell lung cancer (NSCLC), though a big barrier remains, which is epithelial-mesenchymal transition (EMT). Our study aimed to evaluate the function of miR-6884-5p and S100A16 in EMT-aggravated NSCLC. The tumor tissues and adjacent tissues from 92 NSCLC patients were collected to analyze the expression of miR-6884-5p and S100A16. Then lung cancer cell line A549 was co-transfected with miR-6884-5p mimics and S100A16 to further evaluate their function. Compared to adjacent tissues, low expression of miR-6884-5p was observed in the NSCLC tissues and associated with severe NSCLC progression. MiR-6884-5p expression was negatively correlated with EMT in NSCLC. Luciferase assay data revealed that miR-6884-5p could directly bind to the 3'UTR of S100A16 and inhibited the expression of S100A16 in A549 cells. Moreover, miR-6884-5p mimics significantly ameliorated EMT progression, and overexpression of S100A16 could reverse the inhibitory effect of miR-6884-5p in A549 cells. MiR-6884-5p inhibited EMT through directly targeting S100A16 in NSCLC. Our findings suggest that miR-6884-5p could be a diagnostic marker of NSCLC, as well as a potential candidate for NSCLC treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pulmonary and Critical Care Medicine (PCCM) Ward II, Cangzhou Central Hospital, Cangzhou 061000, Hebei, China.
- Department of Geriatrics, Cangzhou Central Hospital, Cangzhou 061000, Hebei, China.
Cite
APA
Zhang, L., Chi, W., Wang, X., Li, J., Li, F., Ma, Y., & Zhang, Q. (2024). The role of miR-6884-5p in epithelial-mesenchymal transition in non-small cell lung cancer. Aging. https://doi.org/10.18632/aging.205474
Vancouver
Zhang L, Chi W, Wang X, Li J, Li F, Ma Y, et al. The role of miR-6884-5p in epithelial-mesenchymal transition in non-small cell lung cancer. Aging. 2024. doi:10.18632/aging.205474
BibTeX
@article{Zhang2024,
author = {Zhang, Lianyong and Chi, Wei and Wang, Xue and Li, Jingjing and Li, Fei and Ma, Yuxia and Zhang, Qianyun},
title = {The role of miR-6884-5p in epithelial-mesenchymal transition in non-small cell lung cancer},
journal = {Aging},
year = {2024},
doi = {10.18632/aging.205474}
}
EUVIMED